Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The last few months have seen a flurry of trial results for investigational agents in Alzheimer's disease (AD). This analysis investigates the different categories of developmental drugs in AD, and provides an outlook to the future of the AD market.
Roche is one of the few pharmaceutical companies that has stayed firmly committed to research and development for central nervous system disorders. Here, Luca Santarelli, Senior Vice President and Head of Neuroscience Research and Early development, discusses why.
Last year saw the largest loss of revenue yet from major drugs due to patent expiries, but a continuation of 2011's higher level of drug approvals and new initiatives to address R&D challenges provide hope for the future.